Total Versus Robotic Assisted Unicompartmental Knee Replacement
NCT05290818
Recruiting
The purpose of this research is to compare the functional outcomes of patients with end stage medial compartment OA of the knee undergoing a conventional mTKA to those undergoing rUKA and to assess the associated cost economics of such technology.
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
11/13/2024
Locations: Nicholas Clement, Edinburgh, Lothian
Conditions: Osteo Arthritis Knee, Arthritis Knee, Arthropathy of Knee
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
ALL
Ages:
All
Trial Updated:
11/13/2024
Locations: Clinical Trial Site, Aurora, Colorado +137 locations
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502
Recruiting
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +46 locations
Conditions: Polycythemia Vera
Register for Updates
The CATALINA Study
NCT05008081
Recruiting
The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Kepler University Hospital, Linz, Not set +17 locations
Conditions: Chronic Obstructive Pulmonary Disease Exacerbation
Register for Updates
Keep-On-Keep-Up (KOKU)
NCT06687135
Recruiting
Falls are the primary cause of fatal and non-fatal accidental injuries in older adults. Around a third of community-dwelling older adults fall per year with high associated personal and societal costs. The World Falls Prevention Guidelines recommend balance challenging, functional exercise programmes for falls prevention but there can be low uptake and adherence in community settings. A digital, NHS approved programme Keep-On-Keep-Up (KOKU) was co-developed with older adults and therapists, to p... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/12/2024
Locations: The University of Manchester, Manchester, Greater Manchester +1 locations
Conditions: Balance, Falls Prevention, Functional Decline
Register for Updates
Polycystic Liver Disease Registry (UK)
NCT04645251
Recruiting
Multicentre, observational registry studying the natural course of polycystic liver disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Radboud University Medical Center, Nijmegen, Not set +1 locations
Conditions: Polycystic Liver Disease
Register for Updates
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312
Recruiting
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Nucleus Network Brisbane, Brisbane, Queensland +3 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Register for Updates
HIFU Ablation of Soft Tissue Sarcoma
NCT05111964
Recruiting
Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years. STS can arise from various tissue types and is comprised of over 50 tumour types. Although STS is treated with a combination of surgery, radiotherapy and chemotherapy, the prognosis is relatively poor with a five-year survival rate of 54%. There is an unmet need for further treatment modalities in STS. High intensity focused ultra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Churchill Hospital, Oxford, Oxfordshire
Conditions: Soft Tissue Sarcoma, Desmoid; Abdominal
Register for Updates
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
NCT05112237
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
11/11/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +28 locations
Conditions: Cardiomyopathy
Register for Updates
Intermittent Carbohydrate Restriction in Cardiometabolic Health
NCT06684834
Recruiting
Metabolic conditions, such as heart disease, type 2 diabetes, and metabolic syndrome, are among the leading causes of disability and mortality worldwide. Identifying innovative lifestyle strategies to reduce metabolic risk remains a public health priority. Further research is essential to understand how low carbohydrate intake influences human metabolism and how intermittent carbohydrate restriction impacts weight loss and metabolic health markers. This study will investigate two interventions... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/09/2024
Locations: University of Bath, Bath, Somerset
Conditions: Obesity and Overweight
Register for Updates
Feasibility of Ambulatory Talc. Pleurodesis
NCT06682936
Recruiting
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: North Tees and Hartlepool NHS foundation trust, Stockton-on Tees, County Durham
Conditions: Malignant Pleural Effusion, Malignancy, Palliative Care
Register for Updates
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486
Recruiting
The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in participants with multiple system atrophy (MSA). The secondary objectives are to evaluate the pharmacodynamic (PD) effect of ION464 on the level of a potential biomarker of target engagement (Parts 1 and 2) and to evaluate the pharmacokinetic (PK) profile of ION464 in serum... Read More
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
11/08/2024
Locations: Medizinische Universität Innsbruck, Innsbruck, Not set +13 locations
Conditions: Multiple System Atrophy
Register for Updates